ExpreS2ion has been awarded SEK 2.7 million for continued development of two malaria vaccine candidates
ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) announces that the Company has been awarded SEK 2.7 million as part of the Horizon 2020-funded OptiMalVax grant consortium, led by Jenner Institute at the University of Oxford, to establish monoclonal Drosophila S2 cell banks for two new malaria vaccine candidates. One targets blood-stage malaria, potentially in combination with the RH5 vaccine candidate that was successfully tested in a Phase IIa clinical trial, and the other is a transmission-blocking vaccine. The ultimate goal of the project is to create a next generation blood-stage